Press Release
Pierre Fabre and the EspeRare Foundation start the EDELIFE clinical trial of a prenatal treatment for a rare genetic disease, XLHED
15 November 2021
Geneva, Switzerland, Castres, France (November 15, 2021) – The EspeRare Foundation and the Pierre Fabre group announced today the start of the EDELIFE clinical trial aimed at confirming the safety and efficacy of ER004, a prenatal treatment for XLHED (X-linked Hypohidrotic Ectodermal Dysplasia), a rare and debilitating congenital disease. If positive, the study could lead to the first approved treatment for XLHED by 2026.
/en/press_release/pierre-fabre-and-the-esperare-foundation-start-the-edelife-clinical-trial-of-a
